A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer.
Clémence LegoupilDidier DebieuvreAurelien MarabelleStefan MichielsRaïssa KapsoBenjamin BesseJulia BonastrePublished in: ERJ open research (2020)
Anti-PD-1 agents for NSCLC treatment are associated with a substantial economic burden.